Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany

Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials.

Source: European Journal of Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Jan A. Stratmann, Friederike C. Althoff, Paula Doebel, Jacqueline Rauh, Arne Trummer, Ali Nuri H ünerlitürkoglu, Nikolaj Frost, Hüsameddin Yildirim, Petros Christopoulos, Oswald Burkhard, Christian Meyer zum Büschenfelde, Aaron Becker von Rose, Jürge Tags: Original Research Source Type: research